This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Click here for Vydura® (rimegepant) Prescribing Information for Great Britain and Northern Ireland. Adverse event reporting information can be found at the bottom of the page.
VYDURA is indicated for:1
In the realm of education and learning, access to information is valuable. This online repository offers a selection of published articles (available as e-Reprints), making it easier for healthcare professionals to access the latest research findings and approaches in managing migraine.
Having a centralised source for information through e-Reprints supports healthcare professionals in improving the lives of those affected by migraine by offering peer reviewed content for the management of migraine.
In order to view the selection of published e-Reprints you will need to register or log in.
Rimegepant, a small molecule calcitonin gene-related peptide receptor antagonist, has shown efficacy in the acute treatment of migraine.
This item is intended to be viewed online
*Oral lyophilisate (in the UK)
Rimegepant is a calcitonin gene-related peptide receptor antagonist that has shown efficacy and safety in the acute treatment of migraine. The authors aimed to compare the efficacy of rimegepant with placebo for preventive treatment of migraine...
This item is intended to be viewed online
This post-hoc analysis from three phase 3 treatment trials of rimegepant 75 mg — an oral small molecule calcitonin gene-related peptide receptor antagonist for the acute treatment of migraine...
This item is intended to be viewed online
A promotional medical education program to support clinical excellence in diagnosing, treating, and managing migraines among HCPs.
To learn more about Vydura and it's impact on Calcitonin Gene-Related Peptide Receptors, visit the Mechanism of Action page below
Learn more about migraines including how to diagnose, the imact on patients and society, patient views, pathopysiological and complete case-based learning
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024